|
CH637297A5
(fr)
*
|
1978-12-05 |
1983-07-29 |
Nestle Sa |
Microbille comprenant un microorganisme et son procede de fabrication.
|
|
US4421736A
(en)
*
|
1982-05-20 |
1983-12-20 |
Merrel Dow Pharmaceuticals Inc. |
Sustained release diethylpropion compositions
|
|
US4507276A
(en)
*
|
1982-08-20 |
1985-03-26 |
Bristol-Myers Company |
Analgesic capsule
|
|
FR2548021B1
(fr)
*
|
1983-06-29 |
1986-02-28 |
Dick P R |
Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
|
|
NL8500724A
(nl)
*
|
1985-03-13 |
1986-10-01 |
Univ Groningen |
Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
|
|
US4755387A
(en)
*
|
1985-03-21 |
1988-07-05 |
The Procter & Gamble Company |
Therapeutic particles
|
|
US4863741A
(en)
*
|
1985-03-25 |
1989-09-05 |
Abbott Laboratories |
Tablet composition for drug combinations
|
|
US4874614A
(en)
*
|
1985-03-25 |
1989-10-17 |
Abbott Laboratories |
Pharmaceutical tableting method
|
|
CA1279574C
(en)
*
|
1985-04-17 |
1991-01-29 |
Jeffrey L. Finnan |
Process for lubricating water-soluble vitamin powders
|
|
US4728512A
(en)
*
|
1985-05-06 |
1988-03-01 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US4794001A
(en)
*
|
1986-03-04 |
1988-12-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US4904476A
(en)
*
|
1986-03-04 |
1990-02-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US5019302A
(en)
*
|
1986-03-12 |
1991-05-28 |
Washington University Technology Associates, Inc. |
Method for granulation
|
|
SE8701479L
(sv)
*
|
1987-04-09 |
1988-10-10 |
Carbomatrix Ab |
Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav
|
|
FI77573C
(fi)
*
|
1987-05-08 |
1989-04-10 |
Orion Yhtymae Oy |
Ny konsistens.
|
|
JP2668880B2
(ja)
*
|
1987-06-23 |
1997-10-27 |
日本油脂株式会社 |
被覆アミノ酸類の製造方法
|
|
DE3721721C1
(de)
*
|
1987-07-01 |
1988-06-09 |
Hoechst Ag |
Verfahren zur Umhuellung von Granulaten
|
|
US5133974A
(en)
*
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
|
US5328697A
(en)
*
|
1992-02-10 |
1994-07-12 |
Mallinckrodt Veterinary, Inc. |
Compositions and processes for the sustained release of drugs
|
|
DE60037345T2
(de)
|
1999-12-10 |
2008-11-13 |
Pfizer Products Inc., Groton |
Pyrrolo(2,3-d)pyrimidin-Verbindungen
|
|
US6544555B2
(en)
*
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
CN1450999A
(zh)
*
|
2000-03-31 |
2003-10-22 |
辉瑞产品公司 |
新的哌嗪衍生物
|
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
EE200300189A
(et)
*
|
2000-10-19 |
2003-10-15 |
Pfizer Products Inc. |
Sillatud piperasiinderivaadid
|
|
SK15722003A3
(sk)
|
2001-06-20 |
2004-08-03 |
Pfizer Products Inc. |
Deriváty kyseliny sulfónovej a ich použitie
|
|
OA12670A
(en)
*
|
2001-10-22 |
2006-06-20 |
Pfizer Prod Inc |
Piperazine derivatives with ccr1 receptor antagonist activity.
|
|
EP1506182A1
(en)
*
|
2002-05-14 |
2005-02-16 |
Pfizer Products Inc. |
Methods for the manufacture of dihydro-furan-2-one derivatives
|
|
BR0309930A
(pt)
*
|
2002-05-14 |
2005-02-09 |
Pfizer Prod Inc |
Derivados do ácido dihidroxihexanóico, seus intermediários e métodos de produção
|
|
PA8575901A1
(es)
*
|
2002-07-18 |
2004-07-20 |
Pfizer Prod Inc |
Derivados de piperidina novedosos
|
|
WO2004014875A1
(en)
*
|
2002-08-12 |
2004-02-19 |
Pfizer Products Inc. |
Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide
|
|
CA2496295C
(en)
|
2002-09-18 |
2010-11-23 |
Michael John Munchhof |
Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
|
|
US20040116441A1
(en)
*
|
2002-10-30 |
2004-06-17 |
Pfizer Inc |
Methods of using sulfonic acid derivatives
|
|
US20040087571A1
(en)
*
|
2002-10-30 |
2004-05-06 |
Pfizer Inc |
Methods of using CCR1 antagonists as immunomodulatory agents
|
|
US20040097554A1
(en)
*
|
2002-10-30 |
2004-05-20 |
Pfizer Inc |
Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
|
|
AU2003278529A1
(en)
*
|
2002-11-21 |
2004-06-15 |
Pfizer Products Inc. |
3-amino-piperidine derivatives and processes for their preparation
|
|
NZ539901A
(en)
*
|
2002-11-26 |
2007-09-28 |
Pfizer Prod Inc |
Method of treatment of transplant rejection
|
|
MXPA05006229A
(es)
*
|
2002-12-13 |
2005-08-19 |
Pfizer Prod Inc |
Derivados de piperazina que contienen fosforo como antagonistas de ccr1.
|
|
PA8591801A1
(es)
|
2002-12-31 |
2004-07-26 |
Pfizer Prod Inc |
Inhibidores benzamidicos del receptor p2x7.
|
|
EP1601672B1
(en)
*
|
2003-02-14 |
2006-07-26 |
Pfizer Products Inc. |
Triazolo-pyridines as anti-inflammatory compounds
|
|
PA8595001A1
(es)
*
|
2003-03-04 |
2004-09-28 |
Pfizer Prod Inc |
Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
|
|
WO2004080982A1
(en)
|
2003-03-11 |
2004-09-23 |
Pfizer Products Inc. |
Pyrazine compounds as transforming growth factor (tgf) inhibitors
|
|
US20050119275A1
(en)
*
|
2003-06-24 |
2005-06-02 |
Pfizer Inc. |
Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
|
|
EP1689407A1
(en)
*
|
2003-11-25 |
2006-08-16 |
Pfizer Products Inc. |
Method of treatment of atherosclerosis
|
|
TW201038578A
(en)
|
2009-01-30 |
2010-11-01 |
Univ Rutgers |
Methods to treat cancer
|
|
US8461102B2
(en)
*
|
2010-03-02 |
2013-06-11 |
George E. Royster, JR. |
Methods and compositions for treating and preventing symptoms of hormonal variations
|
|
KR101987736B1
(ko)
|
2011-03-18 |
2019-06-11 |
젠자임 코포레이션 |
글루코실세라마이드 합성효소 억제제
|
|
KR20140045411A
(ko)
|
2011-05-16 |
2014-04-16 |
젠자임 코포레이션 |
Ｃｘｃｒ４ 길항제의 용도
|
|
EP2755663A4
(en)
|
2011-09-13 |
2015-10-07 |
Ottawa Hospital Res Inst |
MicroRNA Inhibitors
|
|
MA37975B2
(fr)
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
|
US20160031888A1
(en)
|
2013-03-13 |
2016-02-04 |
Boston Biomedical, Inc. |
3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
|
|
AU2014339897A1
(en)
|
2013-10-24 |
2016-04-21 |
Abbvie Inc. |
JAK1 selective inhibitor and uses thereof
|
|
BR112017002001B1
(pt)
|
2014-07-31 |
2022-10-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compostos e composição farmacêutica
|
|
MA41202A
(fr)
|
2014-12-18 |
2017-10-24 |
Genzyme Corp |
Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
|
|
EP3265462A1
(en)
|
2015-03-03 |
2018-01-10 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Fgfr3 antagonists
|
|
TW201642855A
(zh)
|
2015-03-10 |
2016-12-16 |
健臻公司 |
用於治療蛋白質病變之方法
|
|
US12570664B2
(en)
|
2015-10-16 |
2026-03-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
SG10201913990RA
(en)
|
2015-10-16 |
2020-03-30 |
Abbvie Inc |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
CA3029889A1
(en)
|
2016-07-08 |
2018-01-11 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
4-anilino-quinoline compounds as anti-cancer agents
|
|
CN112055706B
(zh)
|
2018-01-05 |
2023-11-10 |
健康和医学国家研究院 |
取代的卤代-喹啉衍生物、其制备方法和应用
|
|
JP2022504228A
(ja)
|
2018-10-03 |
2022-01-13 |
テサロ， インコーポレイテッド |
ニラパリブ遊離塩基の結晶形態
|
|
CN113166071B
(zh)
|
2018-10-03 |
2025-03-21 |
特沙诺有限公司 |
尼拉帕利盐
|
|
CN113645969A
(zh)
|
2019-02-04 |
2021-11-12 |
建新公司 |
用于治疗与溶酶体贮积症相关的症状和病症的方法
|
|
CN114040762A
(zh)
|
2019-02-04 |
2022-02-11 |
建新公司 |
使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
|
|
JP2023512366A
(ja)
|
2020-02-03 |
2023-03-27 |
ジェンザイム・コーポレーション |
リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
|
|
AU2021311131B2
(en)
|
2020-07-24 |
2026-02-19 |
Genzyme Corporation |
Pharmaceutical compositions comprising venglustat
|
|
EP4221700A1
(en)
|
2020-09-30 |
2023-08-09 |
Bioverativ Therapeutics Inc. |
Ampk activators and methods of use thereof
|
|
TW202241888A
(zh)
|
2020-12-23 |
2022-11-01 |
美商健臻公司 |
氘化群落刺激因子-1受體(csf-1r)抑制劑
|
|
WO2023196640A1
(en)
|
2022-04-08 |
2023-10-12 |
Bioverativ Therapeutics Inc. |
Oxindole derivatives as ampk activators for use in the treatment of rare blood disorders
|
|
JP2025541739A
(ja)
|
2022-12-01 |
2025-12-23 |
ジェンザイム・コーポレーション |
Ｃｙｐ３ａ４の強力な又は中程度の阻害剤と組み合わせたベングルスタット
|
|
WO2025074120A1
(en)
|
2023-10-06 |
2025-04-10 |
Imperial College Innovations Limited |
Nanoparticles for extended release drug delivery
|
|
WO2025262570A1
(en)
|
2024-06-17 |
2025-12-26 |
Genzyme Corporation |
Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment
|
|
GB202411975D0
(en)
|
2024-08-14 |
2024-09-25 |
Imperial College Innovations Ltd |
Nanoparticles for extended release drug delivery
|